about
Mitomycin-C-Induced TTP/HUS Treated Successfully with Rituximab: Case Report and Review of the Literature.Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma.Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies.Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare DatabaseCost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare.The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies.Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantationImpact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation.Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.Transplant strategies in relapsed/refractory Hodgkin lymphoma.Incidence and evaluation of incidental abnormal bone marrow signal on magnetic resonance imaging.Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and OpportunitiesEarly Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell TransplantationOutcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17pImmune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell TransplantationSignificant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample DatabaseStandard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell TransplantationSafety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma
P50
Q33408339-7E4B4DA8-BC63-443B-98B4-C84DDA64B615Q35197433-B09CBFF8-1FB0-418E-BDD0-E0455130A459Q36009600-532F9703-FAA5-4A6E-993F-0231ABFA6CA5Q36355144-D7DEB49D-FAD5-4923-A8F1-3299B71D3508Q37066097-4F7B539B-ABE9-4092-BFBE-9A64CA544142Q37382627-C7DEB039-C2DE-490B-86E1-2346F171F466Q38667364-8116321C-D1EC-4F6D-9810-07E015500D27Q40513698-61348105-956C-43B2-8E52-7A4BDB114DCCQ41993908-CB96E7E6-E157-428B-8BC1-B577727E14A7Q49391414-998B295B-96EF-4DDC-B0FA-9F126D85F3B8Q52676516-00E67B68-EA64-4B15-9E42-FFBA1230D296Q55687766-1EBB49F3-91F5-4936-BF95-965D665E1B6DQ89998036-4B4A1883-B44C-4D3E-BA80-E8B6C255C8A1Q90586733-32BFC032-DE8D-4445-AB88-B56B0D8A393FQ90925994-D3185A46-6BC5-42BF-8356-E8A288DCE43DQ90964241-7FFD29C8-AECD-4E6F-9997-361A5D82F507Q91338776-990CA7E4-AD28-4E16-B135-D5E007923F63Q92111791-C52DE04A-6083-4E35-9B53-EA87967BDFA8Q92199213-3E45DFA0-1552-4E42-8A59-F5508E06B5FD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gunjan L Shah
@ast
Gunjan L Shah
@en
Gunjan L Shah
@es
Gunjan L Shah
@nl
Gunjan L Shah
@sl
type
label
Gunjan L Shah
@ast
Gunjan L Shah
@en
Gunjan L Shah
@es
Gunjan L Shah
@nl
Gunjan L Shah
@sl
prefLabel
Gunjan L Shah
@ast
Gunjan L Shah
@en
Gunjan L Shah
@es
Gunjan L Shah
@nl
Gunjan L Shah
@sl
P106
P31
P496
0000-0002-9977-0456